Loading page
Loading page
Loading substance route
In comparison to its often relatively mild accompanying cognitive and visual effects, 5-MeO-DMT seems to have by far the most proportionally intense and overwhelming physical sensations found within the known psychedelic experience.
The physical effects of 5-MeO-DMT can be broken down into ten components all of which progressively intensify proportional to dosage.
The visual geometry that is present throughout this trip does not usually occur and never extends beyond level 7 at its highest state. It is very similar to DMT although significantly smaller in size and more likely to manifest in darkness or without distractions. In terms of appearance, it can be comprehensively described through its variations as intricate in complexity, abstract in form, equally organic and digital in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in sharp and soft edges, small in size, fast in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in its intensity.
The auditory effects of 5-MeO-DMT are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
5-MeO-DMT is considered non-addictive with low abuse potential. Animal self-administration studies, which predict abuse liability, have been unsuccessful, indicating it lacks the pharmacology to initiate or maintain dependence.
5-MeO-DMT is not physically addicting and does not produce physical dependence or withdrawal symptoms.
Deaths from 5-MeO-DMT are rare but have occurred, particularly when combined with MAOIs or other serotonergic substances. The estimated lethal dose relative to typical recreational doses in humans is unknown. The LD50 in animals varies widely by species; sheep appear particularly sensitive (1-5 mg/kg IV) compared to mice.
| Species | Route | Value |
|---|---|---|
| mouse | IV | 48 mg/kg |
Smoking 5-MeO-DMT can cause throat and lung irritation due to the harsh nature of the vapor; severe lung pain has been reported in rare cases, though risk is generally low given the small doses typically used.
Acute cardiovascular effects including increased heart rate and elevated blood pressure occur during intoxication; possible cardiotoxic properties have been suggested but remain unconfirmed.
5-MeO-DMT can trigger latent psychoses in predisposed individuals and may cause lasting psychological effects including PTSD-type reactions, chronic anxiety, and difficulty integrating experiences. Documented cases include multi-day psychotic episodes requiring antipsychotic medication, typically associated with high doses. Permanent disturbances in self- and reality recognition are possible, and individuals with a family history of schizophrenia or early onset mental illness should exercise extreme caution.
Convulsions have been documented in at least one case involving combination with MAOIs, but seizure risk from 5-MeO-DMT alone is not established in the available literature. Muscle contractions, spasms, and tremors are reported physical effects.
5-MeO-DMT has a lengthy history of human use spanning over a millennium. Archaeological evidence from a burial site in Northern Chile, dated to approximately the 8th century A.D., revealed snuffing paraphernalia alongside traces of N,N-DMT, 5-MeO-DMT, and bufotenine. Additional archaeological sites…
Classified as a prohibited substance under the Poisons Standard as a structural analog of N,N-dimethyltryptamine (DMT). No therapeutic use is recognized.
Reportedly not explicitly controlled under Belgian law, although DMT itself is scheduled under the 1971 UN Convention. This status remains unconfirmed.
Not scheduled under the Controlled Drugs and Substances Act. Possession and sale are not specifically prohibited under federal drug law.
Not listed in Government Regulation n. 463/2013 (Nařízení vlády č. 463/2013 Sb), making it legal to possess and sell.
Banned in December 2014 under a government regulation that prohibited over 100 psychoactive chemicals.
Became a controlled substance on February 18, 2003, as recorded in the EU Legal Database.
Listed as a Schedule I controlled substance under national drug legislation. Possession and distribution are prohibited.
Classified as a Class A controlled substance, carrying the most severe legal penalties for possession and distribution in New Zealand.
Became a controlled substance in October 2011 under federal drug legislation.
Classified under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor) via regulation SFS 2004:696 effective October 1, 2004. Sale and possession are prohibited.
Classified as a controlled drug since December 2013. Possession, production, supply, and import are prohibited.
Controlled under the Misuse of Drugs Act 1971 as a Class A drug because it is an ether of 5-HO-DMT (bufotenin), which falls under the tryptamine catch-all clause. Buying or possessing without a license is illegal.
Prohibited under the Suchtmittelgesetz (Narcotics Act) as an ether of N,N-DMT. Possession, production, and sale are illegal without authorization.
Possession, production, and sale are prohibited under Portaria SVS/MS nº 344.
Classified as a controlled substance effective October 2015 under national drug regulations.
Legally restricted to medical or scientific purposes since December 2004. General possession and sale are prohibited.
Listed in Schedule I of the Betäubungsmittelgesetz (Narcotics Act) since 2000. Manufacturing, possession, import, export, purchase, sale, and distribution without a license are prohibited.
Controlled as a Shitei-Yakubutsu (Designated Substance) under the Pharmaceutical Affairs Law. Possession and sale are illegal without authorization.
While not explicitly named in the Opium List, it may be considered a List I controlled substance as an ether of bufotenin. Despite this legal ambiguity, it reportedly remains available through online research chemical vendors.
Prohibited under the controlled substance analogue act since February 2010. Production and sale are illegal.
Not explicitly listed under the Drug and Drug Trafficking Act No. 140 of 1992. However, it could potentially be controlled as an ether of bufotenin or DMT, since ethers and esters of listed substances are also considered controlled.
Specifically named as a controlled substance in Verzeichnis E (Schedule E) of Swiss narcotics legislation.
Listed as a controlled substance under Ukrainian drug legislation.
Added to Schedule I of the Controlled Substances Act effective January 19, 2011. Manufacturing, buying, possessing, or distributing without a DEA license is illegal. Several states including Florida, Louisiana, Nebraska, Oklahoma, and South Dakota had independently scheduled it prior to federal action.
18 sources cited
